Last $3.38 USD
Change Today +0.09 / 2.74%
Volume 62.8K
CBLI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

cleveland biolabs inc (CBLI) Snapshot

Open
$3.29
Previous Close
$3.29
Day High
$3.45
Day Low
$3.28
52 Week High
03/20/14 - $17.46
52 Week Low
02/11/15 - $3.07
Market Cap
11.6M
Average Volume 10 Days
155.3K
EPS TTM
$-2.79
Shares Outstanding
3.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CLEVELAND BIOLABS INC (CBLI)

Related News

No related news articles were found.

cleveland biolabs inc (CBLI) Related Businessweek News

View More BusinessWeek News

cleveland biolabs inc (CBLI) Details

Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with significant medical need. Its lead drug candidates include Entolimod, which is being developed as radiation countermeasure for prevention of death from acute radiation syndrome and as an oncology drug; and CBL0137, which is in two multi-center, single agent, dose escalation Phase I studies in subjects with advanced solid tumors. The company’s clinical stage product candidates comprise CBL0102, which has completed Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and Entolimod, which is in Phase I clinical trials for open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity in advanced cancer patients. Its preclinical stage product candidates include CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin. The company has license agreements and collaborations with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, and Buffalo BioLabs. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

cleveland biolabs inc (CBLI) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $407.6K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $215.3K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $255.5K
Compensation as of Fiscal Year 2013.

cleveland biolabs inc (CBLI) Key Developments

Cleveland BioLabs, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Cleveland BioLabs, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, revenues grants and contracts was $1,390,432 against $3,871,632 a year ago. Loss from operations was $3,451,630 against $2,996,158 a year ago. Net income attributable to the company was $11,271,771 against net loss attributable to the company of $365,247 a year ago. For the full year, revenues grants and contracts was $3,701,899 against $8,487,966 a year ago. Loss from operations was $14,421,935 against $23,076,759 a year ago. Net income attributable to the company was $1,629,104,000 against net loss attributable to the company of $17,262,877 a year ago. Cash flows used in operating activities was $14,455,187 against $23,102,647 a year ago. The increase in net income primarily attributable to a $14.2 million gain on the deconsolidation of the company's joint venture, Incuron LLC.

Cleveland BioLabs Announces Receipt Of Letter From NASDAQ Confirming Compliance With Minimum Bid Price Requirement

Cleveland BioLabs, Inc. announced that on February 12, 2015, the Company received a letter from The NASDAQ Stock Market stating that the Company has regained compliance with Listing Rule 5550(a)(2), maintenance of a minimum bid price of $1.00.

Cleveland BioLabs, Inc. to Report Q4, 2014 Results on Feb 24, 2015

Cleveland BioLabs, Inc. announced that they will report Q4, 2014 results at 10:00 AM, US Eastern Standard Time on Feb 24, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBLI:US $3.38 USD +0.09

CBLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBLI.
View Industry Companies
 

Industry Analysis

CBLI

Industry Average

Valuation CBLI Industry Range
Price/Earnings 5.5x
Price/Sales 2.5x
Price/Book NM Not Meaningful
Price/Cash Flow 6.9x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLEVELAND BIOLABS INC, please visit www.cbiolabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.